MWA
RNTX

Meridian Wealth Advisors’s Rein Therapeutics RNTX Stock Holding History

Meridian Wealth Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37K Hold
28,486
– – ﹤0.01% 202
2025
Q4 		$33K Hold
28,486
– – ﹤0.01% 184
2025
Q3 		$32.6K Hold
28,486
– – ﹤0.01% 186
2025
Q2 		$39.9K Hold
28,486
– – 0.01% 180
2025
Q1 		$50.4K Buy
+28,486
New +$59.8K 0.01% 170

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Meridian Wealth Advisors's RNTX Position: Q1 2026 in Review

Meridian Wealth Advisors held its Rein Therapeutics (RNTX) position steady in Q1 2026 at 28,486 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #202.

Meridian Wealth Advisors first reported a position in RNTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $50.4K in Q1 2025. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Meridian Wealth Advisors held 28,486 shares of Rein Therapeutics worth $37K as of Q1 2026.
  • Meridian Wealth Advisors left its Rein Therapeutics share count unchanged in Q1 2026.
  • Rein Therapeutics made up ﹤0.01% of Meridian Wealth Advisors's portfolio in Q1 2026, its #202 holding.
  • Meridian Wealth Advisors first reported a position in Rein Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Meridian Wealth Advisors's Rein Therapeutics position peaked at $50.4K in Q1 2025.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Meridian Wealth Advisors's 13F filing for Q1 2026, filed 11 May 2026.